This protocol covers the management of atrophic vaginitis in the specific context of genitourinary syndrome of menopause (GSM) complicated by comorbid overactive bladder — a clinical combination where both atrophic genitourinary changes and urinary symptoms are present simultaneously.
Patients with genitourinary syndrome of menopause (GSM) and comorbid overactive bladder, in whom both genitourinary atrophic changes and urinary dysfunction are clinically relevant and require coordinated treatment.
In this scenario, a locally delivered vaginal therapy may be offered to address genitourinary symptoms. The full regimen — including agent, formulation, and all prescribing details — is available in the structured protocol below.
Treatment goal: Improvement of genitourinary and urinary symptoms in patients with GSM and overactive bladder.
DOI: 10.1097/JU.0000000000004589
In patients with GSM and comorbid genitourinary conditions (e.g., overactive bladder), clinicians may offer local low-dose vaginal estrogen to improve genitourinary symptoms.
View source ↗